ORILISSA is different than many other treatment options for endometriosis pain.

Features to consider:

  • ORILISSA is the first FDA-approved pill specifically developed for moderate to severe endometriosis pain in over a decade1
  • It is not a birth control pill, surgery, or an injection. It does not contain hormones1

Custom HTML

ORILISSA is a GnRH receptor antagonist available in 2 oral dosages

ORILISSA is a GnRH antagonist that competes with endogenous gonadotropin-releasing hormone (GnRH) for GnRH receptor occupancy and blocks receptors upon binding1,2

  • ORILISSA competitively binds to GnRH receptors
  • As a GnRH antagonist, ORILISSA binds without stimulating the receptors
ORILISSA is a GnRH-receptor antagonist

GnRH-receptor antagonism1,2

  • When ORILISSA enters the pituitary, it acts like a player in a game of musical chairs, competing with GnRH to sit in the receptor
  • Like a molecular game of musical chairs, GnRH is left with fewer receptors to activate
dose-dependent suppression of LH and FSH

Suppression of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) in a dose-dependent manner1,3,4

  • GnRH receptor antagonism leads to a dose-dependent suppression of LH and FSH observed 4 to 6 hours after administration*

*Does not imply onset of efficacy during this time.

dose-dependent suppression of estradiol

Decreased levels of estradiol and progesterone1,3,4

  • After approximately 24 hours, subsequent suppression of estradiol levels occurs*
  • The degree of suppression is dependent on the dose of ORILISSA
  • Estrogen levels return to baseline 24 to 48 hours after discontinuation


*Does not imply onset of efficacy during this time.


Watch the role of estrogen in endometriosis and the mechanism of action of ORILISSA.